drugset
drugset / Trial / NCT04256759

Dupilumab for the Treatment of Moderate to Severe Chronic Hepatic Pruritus

NCT04256759 ↗

Phase 2 Completed 9 enrolled Mayo Clinic Regeneron Pharmaceuticals · collab
NaSingle-groupOpen-labelTreatment

Summary

To investigate the potential efficacy of dupilumab in the treatment of moderate to severe chronic hepatic pruritus.

Timeline

Start
2020-09-01
Primary completion
2024-09-06
Completion
2024-09-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Dupilumab Monoclonal antibody 300 mg Subcutaneous

Indications

No indication recorded.